Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

Similar articles for PubMed (Select 20637733)


Antiangiogenic effect of licochalcone A.

Kim YH, Shin EK, Kim DH, Lee HH, Park JH, Kim JK.

Biochem Pharmacol. 2010 Oct 15;80(8):1152-9. doi: 10.1016/j.bcp.2010.07.006. Epub 2010 Jul 15.


CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.


Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.

Kimura Y, Sumiyoshi M, Baba K.

Cancer Sci. 2008 Oct;99(10):2083-96. doi: 10.1111/j.1349-7006.2008.00948.x.


KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T.

Cancer Res. 2006 Sep 15;66(18):9134-42.


KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.

Nakamura K, Yamamoto A, Kamishohara M, Takahashi K, Taguchi E, Miura T, Kubo K, Shibuya M, Isoe T.

Mol Cancer Ther. 2004 Dec;3(12):1639-49.


ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF.

Cancer Res. 2002 Aug 15;62(16):4645-55.


Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.

Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM.

Cancer Res. 2003 May 1;63(9):2079-87.


Anti-tumor actions of major component 3'-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation.

Kimura Y, Sumiyoshi M, Baba K.

Cancer Lett. 2008 Jun 28;265(1):84-97. doi: 10.1016/j.canlet.2008.02.009. Epub 2008 Mar 20.


Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.


Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.

Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS.

Mol Cancer Ther. 2007 Feb;6(2):471-83.


Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG.

Cancer Res. 2003 Nov 1;63(21):7301-9.


Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.

Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M.

Cancer Res. 2009 Jul 15;69(14):5893-900. doi: 10.1158/0008-5472.CAN-09-0755. Epub 2009 Jun 30.


Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.

Cancer Res. 2004 May 15;64(10):3586-92.


mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.


Antitumor and antimetastatic effects of licochalcone A in mouse models.

Kim JK, Shin EK, Park JH, Kim YH, Park JH.

J Mol Med (Berl). 2010 Aug;88(8):829-38. doi: 10.1007/s00109-010-0625-2. Epub 2010 Apr 11.


Licochalcone A isolated from licorice suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice.

Kwon HS, Park JH, Kim DH, Kim YH, Park JH, Shin HK, Kim JK.

J Mol Med (Berl). 2008 Nov;86(11):1287-95. doi: 10.1007/s00109-008-0395-2. Epub 2008 Sep 30.


Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.

Murakami K, Sakukawa R, Sano M, Hashimoto A, Shibata J, Yamada Y, Saiki I.

Clin Cancer Res. 1999 Sep;5(9):2304-10.


Indirubin-3'-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis.

Kim JK, Shin EK, Kang YH, Park JH.

J Cell Biochem. 2011 May;112(5):1384-91. doi: 10.1002/jcb.23055.


Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.

Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.

Cancer. 2000 Aug 1;89(3):488-99.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk